85.4%
Buparlisibalpelisibbuparlisib with paclitaxelipatasertib with paclitaxelcapivasertib with paclitaxeltaselisib with fulvestrantcapivasertib plus fulvestrantpictilisib plus fulvestrantfulvestrantbuparlisib plus fulvestrant+1 more
…3-50.7); PFS=12.8 months (95% CI 6.6-18.8); ORR=not available]. Buparlisib plus fulvestrant presented the next best numerical efficacy [OS…